FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2986856572> ?p ?o ?g. }

• W2986856572 endingPage "401" @default.
• W2986856572 startingPage "393" @default.
• W2986856572 abstract "Rituximab is an effective treatment for steroid-dependent/ frequently-relapsing nephrotic syndrome (SDFRNS) in children. However, the optimal rituximab regimen remains unknown. To help determine this we conducted an international, multicenter retrospective study at 11 tertiary pediatric nephrology centers in Asia, Europe and North America of children 1-18 years of age with complicated SDFRNS receiving rituximab between 2005-2016 for 18 or more months follow-up. The effect of rituximab prescribed at three dosing levels: low (375mg/m²), medium (750mg/m²) and high (1125-1500mg/m²), with or without maintenance immunosuppression (defined as concurrent use of corticosteroids, mycophenolate motile or calcineurin inhibition at first relapse or for at least six months following the rituximab treatment) was examined. Among the 511 children (median age 11.5 year, 67% boys), 191, 208 and 112 received low, medium and high dose rituximab, respectively. Within this total cohort of 511 children, 283 (55%) received maintenance immunosuppression. Renal biopsies were performed in 317 children indicating the predominant histology was minimal change disease (74%). Without maintenance immunosuppression, low-dose rituximab had a shorter relapse-free period and a higher relapse risk (8.5 months) than medium (12.7 months; adjusted hazard ratio, 0.62) and high dose (14.3 months; adjusted hazard ratio, 0.50; all significant). With maintenance immunosuppression, the relapse-free survival in low-dose rituximab (14 months) was similar to medium (10.9 months; adjusted hazard ratio, 1.23) and high dose (12.0 months; adjusted hazard ratio, 0.92; all non-significant). Most adverse events were mild. Thus, children receiving low-dose rituximab without maintenance immunosuppression had the shortest relapse-free survival. Hence, both rituximab dose and maintenance immunosuppression have important effects on the treatment outcomes." @default.
• W2986856572 created "2019-11-22" @default.
• W2986856572 creator A5000377652 @default.
• W2986856572 creator A5021247189 @default.
• W2986856572 creator A5033787199 @default.
• W2986856572 creator A5036513936 @default.
• W2986856572 creator A5039683551 @default.
• W2986856572 creator A5039715855 @default.
• W2986856572 creator A5044001336 @default.
• W2986856572 creator A5046288691 @default.
• W2986856572 creator A5047765829 @default.
• W2986856572 creator A5048588130 @default.
• W2986856572 creator A5055568556 @default.
• W2986856572 creator A5062090833 @default.
• W2986856572 creator A5069538810 @default.
• W2986856572 creator A5072072056 @default.
• W2986856572 creator A5082190685 @default.
• W2986856572 creator A5084675851 @default.
• W2986856572 creator A5090555589 @default.
• W2986856572 date "2020-02-01" @default.
• W2986856572 modified "2023-10-16" @default.
• W2986856572 title "Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes" @default.
• W2986856572 cites W1937017173 @default.
• W2986856572 cites W1943152384 @default.
• W2986856572 cites W1973377712 @default.
• W2986856572 cites W1978263554 @default.
• W2986856572 cites W1983663249 @default.
• W2986856572 cites W1984854090 @default.
• W2986856572 cites W1987912630 @default.
• W2986856572 cites W1989529519 @default.
• W2986856572 cites W2003950996 @default.
• W2986856572 cites W2013117089 @default.
• W2986856572 cites W2017206130 @default.
• W2986856572 cites W2022192912 @default.
• W2986856572 cites W2045762096 @default.
• W2986856572 cites W2049948745 @default.
• W2986856572 cites W2052616569 @default.
• W2986856572 cites W2053803732 @default.
• W2986856572 cites W2066000834 @default.
• W2986856572 cites W2068222899 @default.
• W2986856572 cites W2074744239 @default.
• W2986856572 cites W2076316204 @default.
• W2986856572 cites W2091842990 @default.
• W2986856572 cites W2096606489 @default.
• W2986856572 cites W2115135526 @default.
• W2986856572 cites W2124215501 @default.
• W2986856572 cites W2140164312 @default.
• W2986856572 cites W2157484737 @default.
• W2986856572 cites W2168653495 @default.
• W2986856572 cites W2322856447 @default.
• W2986856572 cites W2461176530 @default.
• W2986856572 cites W2508899020 @default.
• W2986856572 cites W2596349277 @default.
• W2986856572 cites W2731755024 @default.
• W2986856572 cites W2789813200 @default.
• W2986856572 cites W2792085519 @default.
• W2986856572 cites W2808954631 @default.
• W2986856572 cites W2885165956 @default.
• W2986856572 cites W2898846390 @default.
• W2986856572 doi "https://doi.org/10.1016/j.kint.2019.09.033" @default.
• W2986856572 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31874801" @default.
• W2986856572 hasPublicationYear "2020" @default.
• W2986856572 type Work @default.
• W2986856572 sameAs 2986856572 @default.
• W2986856572 citedByCount "60" @default.
• W2986856572 countsByYear W29868565722020 @default.
• W2986856572 countsByYear W29868565722021 @default.
• W2986856572 countsByYear W29868565722022 @default.
• W2986856572 countsByYear W29868565722023 @default.
• W2986856572 crossrefType "journal-article" @default.
• W2986856572 hasAuthorship W2986856572A5000377652 @default.
• W2986856572 hasAuthorship W2986856572A5021247189 @default.
• W2986856572 hasAuthorship W2986856572A5033787199 @default.
• W2986856572 hasAuthorship W2986856572A5036513936 @default.
• W2986856572 hasAuthorship W2986856572A5039683551 @default.
• W2986856572 hasAuthorship W2986856572A5039715855 @default.
• W2986856572 hasAuthorship W2986856572A5044001336 @default.
• W2986856572 hasAuthorship W2986856572A5046288691 @default.
• W2986856572 hasAuthorship W2986856572A5047765829 @default.
• W2986856572 hasAuthorship W2986856572A5048588130 @default.
• W2986856572 hasAuthorship W2986856572A5055568556 @default.
• W2986856572 hasAuthorship W2986856572A5062090833 @default.
• W2986856572 hasAuthorship W2986856572A5069538810 @default.
• W2986856572 hasAuthorship W2986856572A5072072056 @default.
• W2986856572 hasAuthorship W2986856572A5082190685 @default.
• W2986856572 hasAuthorship W2986856572A5084675851 @default.
• W2986856572 hasAuthorship W2986856572A5090555589 @default.
• W2986856572 hasConcept C126322002 @default.
• W2986856572 hasConcept C159654299 @default.
• W2986856572 hasConcept C203014093 @default.
• W2986856572 hasConcept C2778930706 @default.
• W2986856572 hasConcept C2780252810 @default.
• W2986856572 hasConcept C2780653079 @default.
• W2986856572 hasConcept C71924100 @default.
• W2986856572 hasConceptScore W2986856572C126322002 @default.
• W2986856572 hasConceptScore W2986856572C159654299 @default.
• W2986856572 hasConceptScore W2986856572C203014093 @default.
• W2986856572 hasConceptScore W2986856572C2778930706 @default.

• next